VJOncology is committed to improving our service to you

Share this video  

VJOncology is committed to improving our service to you

ASCO GI 2021 | Final results from ClarIDHy

Ghassan Abou-Alfa, MD, Memorial Sloan-Kettering Cancer Center, New York City, NY, discusses the final results from ClarIDHy (NCT02989857), a Phase III randomized study of ivosidenib versus placebo in patients with previously treated IDH1-mutated cholangiocarcinoma (CCA). Ivosidenib was found to be well-tolerated and resulted in a favorable overall survival when compared to placebo, demonstrating clinical benefit of ivosidenib in advanced IDH1-mutated CCA. This interview was recorded via an online conference call with The Video Journal of Oncology (VJOncology).

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter